Developing a new treatment for tuberculosis using MmpL3 inhibitors
Official title: Development of the HC2099 series of MmpL3 inhibitors to treat tuberculosis
Funded at Tarn Biosciences, INC. · NIH-10883595 · Data updated 2026-11-12
This study is testing a new medication called HC2099 to help treat tuberculosis, especially the tougher drug-resistant types, by targeting a key protein that the TB bacteria need to survive, with the hope of making treatment easier and more effective for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tarn Biosciences, INC. NIH-funded |
| Lab location | 1 site (East Lansing, United States) |
| Project start | July 6, 2023 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $293,238 |
| NIH project number | 5R41AI167105-02 |
| Project ID | NIH-10883595 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with drug-susceptible or multidrug-resistant tuberculosis.
✕Less likely to help
Patients with other types of infections or those who do not have tuberculosis will not benefit from this research.
What this research studies
This research focuses on creating a new medication, HC2099, to treat tuberculosis (TB), including drug-resistant forms. The approach involves targeting a specific protein, MmpL3, which is crucial for the survival of the TB bacteria. By inhibiting this protein, the researchers aim to develop a treatment that is more effective and has fewer side effects than current therapies, which often require long courses of multiple medications. This could improve patient adherence to treatment and help combat the rise of drug-resistant TB.
Why it matters
Potential benefit: If successful, this research could provide a more effective and easier-to-follow treatment for tuberculosis, potentially saving lives and reducing the spread of drug-resistant strains.
How similar studies have gone: Previous research has shown promise in targeting MmpL3 as a viable approach to treating tuberculosis, indicating that this strategy has potential based on earlier findings.
Where this research is happening
-
Tarn Biosciences, INC.
East Lansing, United States Active
Researchers
- Principal investigator: Vrbanac, John James — Tarn Biosciences, INC.
- Study coordinator: Vrbanac, John James
Related research
Other NIH-funded projects on the same topics.
-
Coronary disease and immune activation in people with HIV and tuberculosis coinfection
This research looks at how having HIV and latent tuberculosis together might raise the risk of heart disease, and what immune changes are involved.
-
Pulmonary rehabilitation to reduce breathing problems after tuberculosis
A program of guided exercise and breathing training to help adults who have recovered from TB breathe better and feel healthier.
-
Pulmonary rehab to reduce breathing troubles after TB
A program of pulmonary rehabilitation is being studied to help adults who have completed TB treatment avoid ongoing lung problems and improve daily breathing.
-
Air pollution and tuberculosis spread in Kampala, Uganda
This project looks at whether dirty air from PM2.5 particles makes tuberculosis more likely to spread within urban slum households in Kampala, Uganda.
-
Air pollution and TB spread in Ugandan urban slums
This project explores whether exposure to air pollution makes tuberculosis more likely to spread within households in a crowded Ugandan slum.
-
Air pollution and TB transmission in Kampala’s urban slums
This project looks at whether air pollution from PM2.5 makes tuberculosis spread more easily from infected people to their neighbors in urban slums of Kampala, Uganda.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.